All News

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Topline TRIUMPH-2 and TRIUMPH-3 results showed retatrutide reduced weight by up to 20.8% in adults with type 2 diabetes and 22.6% in adults with CVD.

The US FDA Fast Track status advances remlifanserin for Alzheimer disease psychosis, with phase 2 RADIANT data expected in fall 2026.

A peer-reviewed study found FDA-cleared IGeneX immunoblot tests detected 58.3% of early Lyme cases vs 30.0% with standard two-tier testing.

Stevan Gonzalez, MD, a transplant specialist, discusses why chronic liver disease often goes undetected and shares practical screening and referral strategies for PCPs.

A new study links semaglutide and tirzepatide to fewer alcohol-related hospitalizations in adults with AUD and diabetes or obesity.

A cross-sectional study linked compulsive smartphone use and limited offline social activity to depressive symptoms in adults aged 60 years or older.

ACOG updated HIV screening and prevention guidance, recommending opt-out lifetime HIV testing and stronger PrEP counseling and prescribing.

A new analysis estimates the 2026 dyslipidemia guideline expands primary prevention statin eligibility to 87.5 million US adults.

FDA accepted Shionogi’s sNDA for cefiderocol for pediatric HABP/VABP and complicated UTI caused by certain Gram-negative bacteria.

The US FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

FDA accepted Axsome’s NDA for AXS-12 for cataplexy in narcolepsy and set a PDUFA target action date of May 1, 2027.

Once-weekly subcutaneous lecanemab matched IV initiation exposure in early Alzheimer disease, but comparative clinical outcome data remain limited.

The 2026 global status report on cancer projects nearly 35 million new cases annually by 2050 and underscores urgent action on prevention and care access.

Phase 2 TRAPEDS-1 trial data show tralokinumab produced consistent pharmacokinetics and tolerability in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

FDA approval makes Differin Epiduo Acne Gel available OTC for patients aged 12 years or older with acne.

Clinicians discuss DKA risk, sick day plans, CGM use, and ketone testing in primary care.